(Reuters) - Data from a small, early-stage safety trial testing Moderna Inc’s (MRNA.O) experimental COVID-19 vaccine does not provide critical data to assess its effectiveness, Stat News reported on Tuesday, citing experts.
Moderna said on Monday the vaccine candidate, the first to be tested in the United States, produced protective antibodies in a small group of healthy volunteers.
The news based on data from eight people who took part in a 45-subject safety trial sent the company’s shares up nearly 20% on Monday and also pushed the markets higher.
Moderna did not immediately respond to a Reuters’ request for comment.
The company’s shares closed down 10.4% at $71.67.
(The story corrects shares close to $71.67, from 471.67, in last paragraph)
Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila